Trials / Terminated
TerminatedNCT00307398
Anecortave Acetate Risk-Reduction Trial (AART)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,596 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg | One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals. |
| OTHER | Anecortave Acetate Vehicle | One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye. |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2006-03-28
- Last updated
- 2012-11-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00307398. Inclusion in this directory is not an endorsement.